Shots: The approval follows the P-II study which involves assessing of Trodelvy in 108 adults with TNBC who had previously received a median of three prior systemic therapies in the […]readmore
Tags : TNBC
Shots: The launch of VENTANA PD-L1 (SP142) follows the US FDA’s approval in Mar’2019, as the first CDx assay involved in identifying triple-negative breast cancer (TNBC) patients associated with 3 […]readmore
MedTech
Pharma
Roche’s Ventana PD-L1 (SP142) Receives FDA’s Approval for Identifying Triple-Negative
Shots: The approval is based on IMpassion130 study assessing Tecentriq + Abraxane vs PBO + Abraxane in patients with advanced or mTNBC with no prior therapy The Ventana PD-L1 (SP142) […]readmore
Shots: The collaboration is for the onset of P-Ib/II trial for assessing Zenith’s ZEN-3694 and Pfizer’s talazoparib in patients with LA or MTNBC Pfizer & Zenith to fund the trial […]readmore